Skip to main content
Erschienen in: Tumor Biology 4/2012

01.08.2012 | Research Article

RETRACTED ARTICLE: Calcium/calmodulin-dependent kinase inhibitor induces growth inhibition, cell cycle arrest, and apoptosis in human choriocarcinoma cells

verfasst von: Noriyuki Takai, Tami Ueda, Naoko Kira, Terukazu Ishii, Toshie Yoshida, Satoko Koga, Masakazu Nishida, Kaei Nasu, Hisashi Narahara

Erschienen in: Tumor Biology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

KN-93, a membrane-permeant calcium/calmodulin-dependent kinase-selective inhibitor, induces apoptosis in some lines of human tumor cells. We investigated the effect of KN-93 in the choriocarcinoma cell line, BeWo. BeWo cells were treated with various concentrations of KN-93, and changes in cell growth, the cell cycle, apoptosis, and related parameters were examined. A WST-1 assay showed that BeWo cells were sensitive to the growth inhibitory effect of KN-93. Cell cycle analysis indicated that exposure to KN-93 decreased the proportion of cells in the S phase and increased the proportion in the G0/G1 phases of the cell cycle. Induction of apoptosis was confirmed by Annexin V staining of externalized phosphatidylserine, by the loss of mitochondrial transmembrane potential, and by antibodies directed against histones from fragmented DNA. This induction occurred in conjunction with the altered expression of genes related to cell growth, malignant phenotype, and apoptosis. These results suggest that KN-93 may serve as a therapeutic agent for the treatment of choriocarcinoma.
Literatur
1.
Zurück zum Zitat Jones WB, Cardinale C, Lewis Jr JL. Management of the high-risk gestational trophoblastic disease: the Memorial Hospital experience. Int J Gynecol Cancer. 1997;7:27–33.CrossRef Jones WB, Cardinale C, Lewis Jr JL. Management of the high-risk gestational trophoblastic disease: the Memorial Hospital experience. Int J Gynecol Cancer. 1997;7:27–33.CrossRef
2.
Zurück zum Zitat Berkowitz RS, Goldstein DP, Bernstein MR. Modified triple chemotherapy in the management of high-risk gestational trophoblastic tumors. Gynecol Oncol. 1984;19:173–81.CrossRef Berkowitz RS, Goldstein DP, Bernstein MR. Modified triple chemotherapy in the management of high-risk gestational trophoblastic tumors. Gynecol Oncol. 1984;19:173–81.CrossRef
3.
Zurück zum Zitat Surwit EA, Hammond CB. Treatment of metastatic trophoblastic disease with poor prognosis. Obstet Gynecol. 1980;55:565–70.PubMed Surwit EA, Hammond CB. Treatment of metastatic trophoblastic disease with poor prognosis. Obstet Gynecol. 1980;55:565–70.PubMed
4.
Zurück zum Zitat Satsu H, Manabe M, Shimizu M. Activation of Ca2+/calmodulin-dependent protein kinase II is involved in hyperosmotic induction of the human taurine transporter. FEBS Lett. 2004;569:123–8.CrossRef Satsu H, Manabe M, Shimizu M. Activation of Ca2+/calmodulin-dependent protein kinase II is involved in hyperosmotic induction of the human taurine transporter. FEBS Lett. 2004;569:123–8.CrossRef
5.
Zurück zum Zitat Rodriguez-Mora O, LaHair M, McCubrey J. FranklinR. Calcium/calmodulin-dependent kinase I and calcium/calmodulin-dependent kinase participate in the control of cell cycle progression in MCF-7 human breast cancer cells. Cancer Res. 2005;65:5408–16.CrossRef Rodriguez-Mora O, LaHair M, McCubrey J. FranklinR. Calcium/calmodulin-dependent kinase I and calcium/calmodulin-dependent kinase participate in the control of cell cycle progression in MCF-7 human breast cancer cells. Cancer Res. 2005;65:5408–16.CrossRef
6.
Zurück zum Zitat Matsushita M, Nairn A. Characterization of the mechanism of regulation of Ca2+/calmodulin-dependent protein kinase I by calmodulin and by Ca2+/calmodulin-dependent protein kinase. J Biol Chem. 1998;273:21473–81.CrossRef Matsushita M, Nairn A. Characterization of the mechanism of regulation of Ca2+/calmodulin-dependent protein kinase I by calmodulin and by Ca2+/calmodulin-dependent protein kinase. J Biol Chem. 1998;273:21473–81.CrossRef
7.
Zurück zum Zitat Tokumitsu H, Brickey D, Glod J, Hidaka H, Sikela J, Soderling T. Activation mechanisms for Ca2+/calmodulin-dependent protein kinase IV. Identification of a brain CaM-kinase IV kinase. J Biol Chem. 1994;269:28640–7.CrossRef Tokumitsu H, Brickey D, Glod J, Hidaka H, Sikela J, Soderling T. Activation mechanisms for Ca2+/calmodulin-dependent protein kinase IV. Identification of a brain CaM-kinase IV kinase. J Biol Chem. 1994;269:28640–7.CrossRef
8.
Zurück zum Zitat Racioppi L, Means AR. Calcium/calmodulin-dependent kinase IV in immune and inflammatory responses: novel routes for an ancient traveler. Trends Immunol. 2008;29:600–7.CrossRef Racioppi L, Means AR. Calcium/calmodulin-dependent kinase IV in immune and inflammatory responses: novel routes for an ancient traveler. Trends Immunol. 2008;29:600–7.CrossRef
9.
Zurück zum Zitat Tombes RM, Grant S, Westin EH, Krystal G. G1 cell cycle arrest and apoptosis are induced in NIH 3T3 cells by KN-93, an inhibitor of CaMK-II (the multifunctional Ca2+/CaM kinase). Cell Growth Differ. 1995;6:1063–70.PubMed Tombes RM, Grant S, Westin EH, Krystal G. G1 cell cycle arrest and apoptosis are induced in NIH 3T3 cells by KN-93, an inhibitor of CaMK-II (the multifunctional Ca2+/CaM kinase). Cell Growth Differ. 1995;6:1063–70.PubMed
10.
Zurück zum Zitat Kawamura K, Grabowski D, Krivacic K, Hidaka H, Ganapathi R. Cellular events involved in the sensitization of etoposide-resistant cells by inhibitors of calcium–calmodulin-dependent processes. Role for effects on apoptosis, DNA cleavable complex, and phosphorylation. Biochem Pharmacol. 1996;52:1903–9.CrossRef Kawamura K, Grabowski D, Krivacic K, Hidaka H, Ganapathi R. Cellular events involved in the sensitization of etoposide-resistant cells by inhibitors of calcium–calmodulin-dependent processes. Role for effects on apoptosis, DNA cleavable complex, and phosphorylation. Biochem Pharmacol. 1996;52:1903–9.CrossRef
11.
Zurück zum Zitat Sumi M, Kiuchi K, Ishikawa T, Ishii A, Hagiwara M, Nagatsu T, Hidaka H. The newly synthesized selective Ca2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. Biochem Biophys Res Commun. 1991;181:968–75.CrossRef Sumi M, Kiuchi K, Ishikawa T, Ishii A, Hagiwara M, Nagatsu T, Hidaka H. The newly synthesized selective Ca2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. Biochem Biophys Res Commun. 1991;181:968–75.CrossRef
12.
Zurück zum Zitat Kahl C, Means A. Regulation of cyclin D1/Cdk4 complexes by calcium/calmodulin-dependent protein kinase I. J Biol Chem. 2004;279:15411–9.CrossRef Kahl C, Means A. Regulation of cyclin D1/Cdk4 complexes by calcium/calmodulin-dependent protein kinase I. J Biol Chem. 2004;279:15411–9.CrossRef
13.
Zurück zum Zitat Shang S, Takai N, Nishida M, Miyazaki T, Nasu K, Miyakawa I. CaMKIV expression is associated with clinical stage and PCNA labeling index in endometrial carcinoma. Int J Mol Med. 2003;11:181–6.PubMed Shang S, Takai N, Nishida M, Miyazaki T, Nasu K, Miyakawa I. CaMKIV expression is associated with clinical stage and PCNA labeling index in endometrial carcinoma. Int J Mol Med. 2003;11:181–6.PubMed
14.
Zurück zum Zitat Takai N, Ueda T, Nasu K, Yamashita S, Toyofuku M, Narahara H. Targeting calcium/calmodulin-dependence kinase I and II as a potential anti-proliferation remedy for endometrial carcinomas. Cancer Lett. 2009;277:235–43.CrossRef Takai N, Ueda T, Nasu K, Yamashita S, Toyofuku M, Narahara H. Targeting calcium/calmodulin-dependence kinase I and II as a potential anti-proliferation remedy for endometrial carcinomas. Cancer Lett. 2009;277:235–43.CrossRef
15.
Zurück zum Zitat Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, et al. Histone deacetylase inhibitors have a profound anti-growth activity in endometrial cancer cells. Clin Cancer Res. 2004;10:1141–9.CrossRef Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, et al. Histone deacetylase inhibitors have a profound anti-growth activity in endometrial cancer cells. Clin Cancer Res. 2004;10:1141–9.CrossRef
16.
Zurück zum Zitat Takai N, Ueda T, Nishida M, Nasu K, Narahara H. Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int J Mol Med. 2008;21:637–43.PubMed Takai N, Ueda T, Nishida M, Nasu K, Narahara H. Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int J Mol Med. 2008;21:637–43.PubMed
17.
Zurück zum Zitat Rimon G, Bazenet CE, Philpott KL, Rubin LL. Increased surface phosphatidylserine is an early marker of neuronal apoptosis. J Neurosci Res. 1997;48:563–70.CrossRef Rimon G, Bazenet CE, Philpott KL, Rubin LL. Increased surface phosphatidylserine is an early marker of neuronal apoptosis. J Neurosci Res. 1997;48:563–70.CrossRef
18.
Zurück zum Zitat Chen Y, Kramer DL, Diegelman P, Vujcic S, Porter CW. Apoptotic signaling in polyamine analogue-treated SK-MEL-28 human melanoma cells. Cancer Res. 2001;61:6437–44.PubMed Chen Y, Kramer DL, Diegelman P, Vujcic S, Porter CW. Apoptotic signaling in polyamine analogue-treated SK-MEL-28 human melanoma cells. Cancer Res. 2001;61:6437–44.PubMed
19.
Zurück zum Zitat Takai N, Ueda T, Nasu K, Narahara H. Erucylphosphocholine shows a strong anti-growth activity in human endometrial and ovarian cancer cells. Gynecol Oncol. 2008;111:336–43.CrossRef Takai N, Ueda T, Nasu K, Narahara H. Erucylphosphocholine shows a strong anti-growth activity in human endometrial and ovarian cancer cells. Gynecol Oncol. 2008;111:336–43.CrossRef
20.
Zurück zum Zitat Johnson D, Walker C. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 1999;39:295–312.CrossRef Johnson D, Walker C. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 1999;39:295–312.CrossRef
21.
Zurück zum Zitat Sherr C. G1 phase progression: cycling on cue. Cell. 1994;79:551–5.CrossRef Sherr C. G1 phase progression: cycling on cue. Cell. 1994;79:551–5.CrossRef
22.
Zurück zum Zitat Kyushima N, Watanabe J, Hata H, Jobo T, Kameya T, Kuramoto H. Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables. J Cancer Res Clin Oncol. 2002;128:307–12.CrossRef Kyushima N, Watanabe J, Hata H, Jobo T, Kameya T, Kuramoto H. Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables. J Cancer Res Clin Oncol. 2002;128:307–12.CrossRef
Metadaten
Titel
RETRACTED ARTICLE: Calcium/calmodulin-dependent kinase inhibitor induces growth inhibition, cell cycle arrest, and apoptosis in human choriocarcinoma cells
verfasst von
Noriyuki Takai
Tami Ueda
Naoko Kira
Terukazu Ishii
Toshie Yoshida
Satoko Koga
Masakazu Nishida
Kaei Nasu
Hisashi Narahara
Publikationsdatum
01.08.2012
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2012
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0339-x

Weitere Artikel der Ausgabe 4/2012

Tumor Biology 4/2012 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.